AviadoBio presents vMiX RNA silencing platform and preclinical programme data
A single IV dose of AVB-406 lowers tau in mice for six months; pIND is complete and first-in-human is planned for 2027. SNCA and SOD1 programmes also show knockdown.
See the latest news and media coverage for AviadoBio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Gene therapy biotechnology company focused on neurodegenerative diseases
aviadobio.comLast updated
In short: AviadoBio reported new vMiX preclinical results and planned AVB-406’s first-in-human study for 2027.
A single IV dose of AVB-406 lowers tau in mice for six months; pIND is complete and first-in-human is planned for 2027. SNCA and SOD1 programmes also show knockdown.
All 17 participants dosed across four ascending cohorts tolerated AVB-101 and its intrathalamic procedure, with no related serious adverse events, dose-limiting toxicity or immunosuppression required. Dose-dependent rises in CSF progranulin are seen.
AVB-101 shows dose-dependent increases in cerebrospinal fluid progranulin across four dose cohorts, with serum NfL at or below baseline at 52 weeks and no serious treatment-related adverse events.
Astellas makes a $20 million equity investment and up to $30 million in upfront payments, with up to $2.18 billion in milestone payments plus royalties.
AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced new preclinical data for AVB-406, its...
AVB-101 continues to be well tolerated, with no serious adverse events related to treatment to date and no immunosuppression required AviadoBio, a pioneering gene therapy...
Astellas Pharma is spreading its bets in neurodegenerative disorders, committing $50 million to AviadoBio for the opportunity to license its lead program, an experimental gene...
The lead program of AviadoBio is a gene therapy for frontotemporal dementia. The London-based startup plans to use the Series A round of funding to...
Track AviadoBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AviadoBio and other trending companies.